Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.63 |
| ▸ | EGFR | P00533 | 14/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949241 | 0.91 | ERBB2 (0.74) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL11903204 | 0.87 | EGFR (0.56) | ERBB2EGFRERBB4 | |
| SCHEMBL11902913 | 0.86 | EGFR (0.53) | ERBB2EGFRERBB4 | |
| SCHEMBL22967949 | 0.84 | ERBB2 (0.57) | ERBB2EGFRLCKKCNH2 | |
| SCHEMBL17476605 | 0.83 | EGFR (0.51) | ERBB2EGFRERBB4 | |
| SCHEMBL10080877 | 0.82 | EGFR (0.61) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL21882884 | 0.82 | EGFR (0.67) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL11903303 | 0.82 | EGFR (0.49) | ERBB2EGFRERBB4 | |
| SCHEMBL11902704 | 0.80 | EGFR (0.49) | ERBB2EGFRERBB4 | |
| SCHEMBL11903198 | 0.79 | EGFR (0.74) | ERBB2EGFRLCKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-9101632-B2 | Kinase inhibitors, prodrug forms thereof and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-08-11 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, ERBB3 | ERBB2 1/4885EGFR 110/4885LCK 436/4885 |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, MAP3K19 | ERBB2 1/4885EGFR 110/4885LCK 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.